

Table S1. Baseline characteristics of the matched cohort

	IB-sparing (n = 72)	Non-IB-sparing (n = 24)	SMD	p-value
Age (yr)	49.0 (41.5–57.5)	49.5 (44.0–61.0)	0.03	0.81
Sex			NA	0.06
Male	49 (68.1)	21 (87.5)		
Female	23 (31.9)	03 (12.5)		
Histology			NA	0.16
WHO I	05 (6.9)	04 (16.7)		
WHO II–III	67 (93.1)	20 (83.3)		
T stage			NA	0.91
T1–2	38 (52.8)	13 (54.2)		
T3–4	34 (47.2)	11 (45.8)		
N stage			< 0.001	1
N0–1	18 (25.0)	06 (25.0)		
N2–3	54 (75.0)	18 (75.0)		
Stage group			< 0.001	1
I–II	06 (8.3)	02 (8.3)		
III–IVA	66 (91.7)	22 (91.7)		
Positive bilateral cervical LNs			< 0.001	1
No	27 (37.5)	09 (37.5)		
Yes	45 (62.5)	15 (62.5)		
Size of LN level IIA ≥ 20 mm and/or LN level IIA with ES			< 0.001	1
No	18 (25.0)	06 (25.0)		
Yes	54 (75.0)	18 (75.0)		
Chemotherapy			NA	0.48
No	02 (2.8)	01 (4.2)		
Concurrent ± sequential	66 (91.7)	23 (95.8)		
Sequential	04 (5.6)	00 (0)		

Values are presented as median (range) or number (%).

WHO, World Health Organization; LN, lymph node; ES, extra-capsular spread; SMD, standardized mean difference.